Breckenridge Pharmaceutical, Inc. is voluntarily recalling a single lot of its Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg, because of possible metal contamination, according to a notice posted by the U.S. Food and Drug Administration.

The company announced the recall on Nov. 16, 2026. The FDA posted the notice on Nov. 20, 2026.

Breckenridge said use of capsules from the affected lot could cause cuts to soft tissues in the mouth, esophagus, stomach, or intestine. The company said the lot used intermediate material thought to be the source of metal detected in a different lot that was not released. Breckenridge said it has not received reports of adverse events judged to be linked to this recall.

The recall covers one lot of 60 mg extended-release propranolol capsules in 100-count bottles. The lot number is PK25110035, with National Drug Code (NDC) 51991-817-01 and an expiration date of May 2029. Breckenridge said the product was manufactured by Adare Pharma Solutions. The company said the recalled lot was distributed nationwide to wholesalers and pharmacies between Oct. 26, 2026, and Nov. 4, 2026.

The company advised consumers to stop using capsules from the recalled lot and contact a physician or other health care provider for medical advice and replacement instructions. It also said consumers should take any remaining capsules from the recalled lot back to the dispensing pharmacy. Breckenridge said wholesalers, pharmacies, and other retail entities should check inventory, quarantine any affected product, and not distribute or dispense it. Anyone who redistributed the product should alert their downstream accounts through the retail level, the notice said.

Questions about the recall can be directed to Qualanex, Breckenridge’s designated recall service provider, at 1-855-736-0807 or recall@qualanex.com, Monday through Friday, 9:00 a.m. to 5:00 p.m. Eastern Time. The company said adverse reactions or quality problems may be reported to the FDA’s MedWatch program online, by mail, or by fax. The notice said the recall is being conducted with the knowledge of the FDA.

On Nov. 9, 2026, Eugia US LLC said it recalled one lot of vancomycin injection after a glass particle was found inside a vial.